LMR Partners’s BridgeBio Pharma BBIO Stock Holding History

LMR Partners’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-107,700	Closed	-$8.24M	–	1468
2025 Q4	$8.24M	Hold	107,700	–	–	0.02%	441
2025 Q3	$5.59M	Hold	107,700	–	–	0.02%	481
2025 Q2	$4.65M	Hold	107,700	–	–	0.03%	460
2025 Q1	$3.72M	Buy	+107,700	New	+$3.63M	0.03%	504
2024 Q3	–	Sell	-87,100	Closed	-$2.21M	–	1299
2024 Q2	$2.21M	Buy	87,100 +47,100	+118%	+$1.29M	0.02%	526
2024 Q1	$1.24M	Sell	40,000 -40,000	-50%	-$1.36M	0.01%	632
2023 Q4	$3.23M	Buy	+80,000	New	+$2.4M	0.04%	400
2023 Q3	–	Sell	-1,055,200	Closed	-$18.1M	–	942
2023 Q2	$18.1M	Buy	+1,055,200	New	+$15.9M	0.2%	111

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LMR Partners's BBIO Position: Q4 2025 in Review

LMR Partners sold out of BridgeBio Pharma (BBIO) in Q4 2025, closing a stake of 5,000 shares — an estimated $328K sold.

LMR Partners first reported a position in BBIO in Q2 2023 and held it in 6 quarters. The position peaked at $2.67M in Q3 2024. 432 funds tracked by Wall St. Rank hold BBIO as of Q4 2025.

LMR Partners reported no remaining BridgeBio Pharma position as of Q4 2025 after selling out during the quarter.
LMR Partners sold 5,000 BridgeBio Pharma shares in Q4 2025, an estimated $328K.
LMR Partners first reported a position in BridgeBio Pharma in Q2 2023 and held it in 6 quarters.
LMR Partners's BridgeBio Pharma position peaked at $2.67M in Q3 2024.
432 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2025.

Based on LMR Partners's 13F filing for Q4 2025, filed 17 Feb 2026.